Hudson Bay Capital Management’s Regenxbio RGNX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.7M Buy
225,000
+45,000
+25% +$373K 0.01% 741
2026
Q1
$1.51M Buy
180,000
+40,000
+29% +$420K 0.01% 813
2025
Q4
$2.02M Sell
140,000
-60,000
-30% -$748K 0.01% 715
2025
Q3
$1.93M Sell
200,000
-20,000
-9% -$177K 0.01% 763
2025
Q2
$1.81M Sell
220,000
-75,000
-25% -$628K 0.01% 826
2025
Q1
$2.11M Sell
295,000
-13,100
-4% -$97.4K 0.01% 814
2024
Q4
$2.38M Buy
308,100
+93,100
+43% +$874K 0.01% 632
2024
Q3
$2.26M Buy
215,000
+50,000
+30% +$610K 0.01% 554
2024
Q2
$1.93M Buy
165,000
+120,100
+267% +$1.87M 0.01% 534
2024
Q1
$946K Sell
44,900
-45,100
-50% -$803K 0.01% 543
2023
Q4
$1.62M Sell
90,000
-25,000
-22% -$440K 0.01% 477
2023
Q3
$1.89M Buy
115,000
+30,000
+35% +$544K 0.01% 491
2023
Q2
$1.7M Buy
85,000
+24,200
+40% +$466K 0.01% 526
2023
Q1
$1.15M Buy
60,800
+15,800
+35% +$350K 0.01% 576
2022
Q4
$1.02M Buy
45,000
+25,000
+125% +$565K 0.01% 686
2022
Q3
$529K Sell
20,000
-50,000
-71% -$1.48M ﹤0.01% 890
2022
Q2
$1.73M Buy
70,000
+5,000
+8% +$125K 0.01% 835
2022
Q1
$2.16M Hold
65,000
0.03% 679
2021
Q4
$2.13M Buy
65,000
+15,000
+30% +$511K 0.02% 660
2021
Q3
$2.1M Sell
50,000
-27,500
-35% -$990K 0.03% 612
2021
Q2
$3.01M Buy
77,500
+31,360
+68% +$1.12M 0.04% 506
2021
Q1
$1.57M Buy
46,140
+6,140
+15% +$262K 0.02% 613
2020
Q4
$1.81M Sell
40,000
-223,000
-85% -$7.79M 0.02% 399
2020
Q3
$7.24M Buy
263,000
+43,000
+20% +$1.4M 0.11% 166
2020
Q2
$8.1M Buy
220,000
+95,000
+76% +$3.54M 0.14% 129
2020
Q1
$4.05M Sell
125,000
-15,000
-11% -$625K 0.1% 183
2019
Q4
$5.74M Buy
140,000
+50,406
+56% +$1.99M 0.13% 152
2019
Q3
$3.19M Buy
+89,594
New +$3.63M 0.09% 209
2018
Q3
Sell
-40,000
Closed -$2.87M 870
2018
Q2
$2.87M Sell
40,000
-50,000
-56% -$2.39M 0.04% 432
2018
Q1
$2.69M Buy
90,000
+15,000
+20% +$437K 0.06% 382
2017
Q4
$2.49M Buy
75,000
+55,000
+275% +$1.66M 0.05% 279
2017
Q3
$659K Buy
+20,000
New +$450K 0.02% 319

Other funds holding RGNX

Hudson Bay Capital Management's RGNX Position: Q2 2026 in Review

Hudson Bay Capital Management increased its Regenxbio (RGNX) stake by 25% in Q2 2026, buying an estimated $373K and bringing the position to 225,000 shares worth $2.7M. The position accounts for 0.01% of the portfolio, ranked #741.

Hudson Bay Capital Management first reported a position in RGNX in Q3 2017 and has held it in 32 quarters since. The position peaked at $8.1M in Q2 2020. 165 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.

  • Hudson Bay Capital Management held 225,000 shares of Regenxbio worth $2.7M as of Q2 2026.
  • Hudson Bay Capital Management bought 45,000 Regenxbio shares in Q2 2026, an estimated $373K.
  • Regenxbio made up 0.01% of Hudson Bay Capital Management's portfolio in Q2 2026, its #741 holding.
  • Hudson Bay Capital Management first reported a position in Regenxbio in Q3 2017 and has held it in 32 quarters since.
  • Hudson Bay Capital Management's Regenxbio position peaked at $8.1M in Q2 2020.
  • 165 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.